mAb-话题@MedSci

#mAb#

1302篇内容 | 2845人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912890, encodeId=cddf191289034, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, objectType=article, longId=736915, objectId=4bffe369156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bffe369156f, replyNumber=0, likeNumber=74, createdTime=2023-05-11, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bffe369156f, moduleTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bffe369156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912846, encodeId=17cd1912846f9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, objectType=article, longId=724681, objectId=ae69e2468173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae69e2468173, replyNumber=0, likeNumber=81, createdTime=2022-10-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae69e2468173, moduleTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae69e2468173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912835, encodeId=ab5819128352c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：Avelumab+Trabectedin联合治疗晚期脂肪/平滑肌肉瘤, objectType=article, longId=723520, objectId=7741e235204b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7741e235204b, replyNumber=0, likeNumber=62, createdTime=2022-07-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7741e235204b, moduleTitle=Clin Cancer Res：Avelumab+Trabectedin联合治疗晚期脂肪/平滑肌肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7741e235204b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912782, encodeId=e4221912e82d6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, objectType=article, longId=295111, objectId=e91429511199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91429511199, replyNumber=0, likeNumber=50, createdTime=2022-02-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91429511199, moduleTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e91429511199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912889, encodeId=9fd5191288912, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, objectType=article, longId=736911, objectId=1981e36911b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1981e36911b5, replyNumber=0, likeNumber=73, createdTime=2023-04-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1981e36911b5, moduleTitle=欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1981e36911b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912894, encodeId=ac611912894c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, objectType=article, longId=737431, objectId=c616e3743158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c616e3743158, replyNumber=0, likeNumber=77, createdTime=2023-06-06, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c616e3743158, moduleTitle=J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c616e3743158)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912884, encodeId=1ff9191288479, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Prasinezumab治疗帕金森病再度失败，aSyn靶向免疫疗法前路茫茫, objectType=article, longId=734861, objectId=5977e348614f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5977e348614f, replyNumber=0, likeNumber=86, createdTime=2022-12-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5977e348614f, moduleTitle=NEJM：Prasinezumab治疗帕金森病再度失败，aSyn靶向免疫疗法前路茫茫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5977e348614f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912839, encodeId=c605191283983, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, objectType=article, longId=723788, objectId=3020e23788de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3020e23788de, replyNumber=0, likeNumber=56, createdTime=2022-06-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3020e23788de, moduleTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3020e23788de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912722, encodeId=69f81912e22d8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, objectType=article, longId=221034, objectId=5e2522103406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e2522103406, replyNumber=0, likeNumber=88, createdTime=2022-02-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e2522103406, moduleTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e2522103406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912788, encodeId=73981912e880e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？, objectType=article, longId=295417, objectId=c68f29541e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c68f29541e66, replyNumber=0, likeNumber=84, createdTime=2022-04-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c68f29541e66, moduleTitle=Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c68f29541e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912787, encodeId=b6f21912e877a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, objectType=article, longId=295315, objectId=4e7b295315f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7b295315f7, replyNumber=0, likeNumber=70, createdTime=2022-03-09, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7b295315f7, moduleTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7b295315f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912756, encodeId=e8d01912e563e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=293025, objectId=724d293025d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724d293025d7, replyNumber=0, likeNumber=34, createdTime=2022-08-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724d293025d7, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724d293025d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912727, encodeId=f3ec1912e272b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：中性粒细胞/淋巴细胞比值(NLR)与avelumab联合阿昔替尼或舒尼替尼治疗晚期肾细胞癌（RCC）疗效的关系: 来自JAVELIN Renal 101研究, objectType=article, longId=221216, objectId=48642212160d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48642212160d, replyNumber=0, likeNumber=56, createdTime=2022-05-16, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48642212160d, moduleTitle=Clin Cancer Res：中性粒细胞/淋巴细胞比值(NLR)与avelumab联合阿昔替尼或舒尼替尼治疗晚期肾细胞癌（RCC）疗效的关系: 来自JAVELIN Renal 101研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48642212160d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912828, encodeId=2cd81912828ef, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, objectType=article, longId=301648, objectId=93a0301648a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a0301648a6, replyNumber=0, likeNumber=83, createdTime=2022-10-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a0301648a6, moduleTitle=NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a0301648a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912773, encodeId=007d1912e739e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA Dermatol：特应性皮炎患者使用Dupilumab的治疗结果, objectType=article, longId=294355, objectId=83da29435514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83da29435514, replyNumber=0, likeNumber=98, createdTime=2022-03-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83da29435514, moduleTitle=JAMA Dermatol：特应性皮炎患者使用Dupilumab的治疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83da29435514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912878, encodeId=b53c19128e8d6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, objectType=article, longId=732675, objectId=84ece326750e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ece326750e, replyNumber=0, likeNumber=92, createdTime=2022-09-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ece326750e, moduleTitle=Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ece326750e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912753, encodeId=3e491912e53e6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV:Risankizumab和Ixekizumab治疗生殖器银屑病的比较, objectType=article, longId=292962, objectId=4e8d292962c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e8d292962c5, replyNumber=0, likeNumber=64, createdTime=2022-02-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e8d292962c5, moduleTitle=JEADV:Risankizumab和Ixekizumab治疗生殖器银屑病的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e8d292962c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912784, encodeId=58371912e84f9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, objectType=article, longId=295314, objectId=762829531471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=762829531471, replyNumber=0, likeNumber=60, createdTime=2022-11-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=762829531471, moduleTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=762829531471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912720, encodeId=40c21912e20a8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, objectType=article, longId=220795, objectId=abf7220e9596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf7220e9596, replyNumber=0, likeNumber=59, createdTime=2022-06-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf7220e9596, moduleTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abf7220e9596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912836, encodeId=a810191283699, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=BA.2有更强的免疫逃逸能力，特效药sotrovimab对其无效了！, objectType=article, longId=723600, objectId=c3e6e23600a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3e6e23600a6, replyNumber=0, likeNumber=58, createdTime=2022-04-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3e6e23600a6, moduleTitle=BA.2有更强的免疫逃逸能力，特效药sotrovimab对其无效了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3e6e23600a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌

2023-05-11

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果

2022-10-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：Avelumab+Trabectedin联合治疗晚期脂肪/平滑肌肉瘤

2022-07-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%

2022-02-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

欧盟批准双特异性抗体Tecvayli（teclistamab）治疗成人复发/难治性多发性骨髓瘤（RRMM）

2023-04-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Sacituzumab govitecan治疗内分泌耐药的HR+/HER2– 晚期乳腺癌

2023-06-06

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Prasinezumab治疗帕金森病再度失败，aSyn靶向免疫疗法前路茫茫

2022-12-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后

2022-06-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关

2022-02-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？

2022-04-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效

2022-03-09

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-08-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：中性粒细胞/淋巴细胞比值(NLR)与avelumab联合阿昔替尼或舒尼替尼治疗晚期肾细胞癌（RCC）疗效的关系: 来自JAVELIN Renal 101研究

2022-05-16

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Trastuzumab deruxtecan vs Trastuzumab emtansine治疗HER2阳性转移性乳腺癌

2022-10-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA Dermatol：特应性皮炎患者使用Dupilumab的治疗结果

2022-03-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Oncol：双抗Mosunetuzumab治疗复发或难治性滤泡性淋巴瘤的疗效

2022-09-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV:Risankizumab和Ixekizumab治疗生殖器银屑病的比较

2022-02-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系

2022-11-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性

2022-06-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

BA.2有更强的免疫逃逸能力，特效药sotrovimab对其无效了！

2022-04-22

科室
- - 订阅+
  - 更多科室
工具
服务